Next Generation Sequencing for Gene Fusion Analysis in Lung Cancer: A Literature Review
- PMID: 32726941
- PMCID: PMC7460167
- DOI: 10.3390/diagnostics10080521
Next Generation Sequencing for Gene Fusion Analysis in Lung Cancer: A Literature Review
Abstract
Gene fusions have a pivotal role in non-small cell lung cancer (NSCLC) precision medicine. Several techniques can be used, from fluorescence in situ hybridization and immunohistochemistry to next generation sequencing (NGS). Although several NGS panels are available, gene fusion testing presents more technical challenges than other variants. This is a PubMed-based narrative review aiming to summarize NGS approaches for gene fusion analysis and their performance on NSCLC clinical samples. The analysis can be performed at DNA or RNA levels, using different target enrichment (hybrid-capture or amplicon-based) and sequencing chemistries, with both custom and commercially available panels. DNA sequencing evaluates different alteration types simultaneously, but large introns and repetitive sequences can impact on the performance and it does not discriminate between expressed and unexpressed gene fusions. RNA-based targeted approach analyses and quantifies directly fusion transcripts and is more accurate than DNA panels on tumor tissue, but it can be limited by RNA quality and quantity. On liquid biopsy, satisfying data have been published on circulating tumor DNA hybrid-capture panels. There is not a perfect method for gene fusion analysis, but NGS approaches, though still needing a complete standardization and optimization, present several advantages for the clinical practice.
Keywords: gene fusions; lung cancer; next generation sequencing; solid and liquid biopsy.
Conflict of interest statement
Authors have no conflict of interest to declare.
Figures
References
-
- Lindeman N.I., Cagle P.T., Aisner D.L., Arcila M.E., Beasley M.B., Bernicker E.H., Colasacco C., Dacic S., Hirsch F.R., Kerr K., et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch. Pathol. Lab. Med. 2018;142:321–346. - PubMed
-
- Pinsolle J., McLeer-Florin A., Giaj Levra M., de Fraipont F., Emprou C., Gobbini E., Toffart A.-C. Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine with Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine. Front. Med. 2019;6:233. - PMC - PubMed
-
- Armstrong F., Duplantier M.-M., Trempat P., Hieblot C., Lamant L., Espinos E., Racaud-Sultan C., Allouche M., Campo E., Delsol G., et al. Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells. Oncogene. 2004;23:6071–6082. doi: 10.1038/sj.onc.1207813. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
